Literature DB >> 12193537

Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling.

Kimberly R Kalli1, Oluwole I Falowo, Laurie K Bale, Michael A Zschunke, Patrick C Roche, Cheryl A Conover.   

Abstract

The insulin receptor mediates a proliferative response in certain transformed cells, but little is known about its function in ovarian cancer. We used human epithelial ovarian carcinoma cell lines and lifespan-extended normal ovarian surface epithelial (OSE) cells to examine (125)I-insulin binding and mitogenic responses to insulin. All cancer cell and OSE cultures specifically bound (125)I-insulin. Except for OV202, the carcinoma lines had elevated insulin binding compared with OSE cells. All carcinoma lines except OV202 expressed insulin receptor as detected by flow cytometry and increased (3)H-thymidine incorporation or cell number in response to 0.1-10 nM insulin. Interestingly, similar concentrations of IGF-II also induced proliferation of the insulin-responsive cancer cell lines and displaced (125)I-insulin binding. Direct binding of (125)I-IGF-II to the insulin receptor was visualized by cross-linking and immunoprecipitation. Binding of IGF-II to the insulin receptor and a proliferative effect of insulin suggest the presence of insulin receptor isoform A. Real-time PCR analyses confirm that insulin receptor isoform A expression predominates over isoform B expression in the ovarian carcinoma cell lines. This report suggests that the insulin receptor may play a role in the regulation of ovarian cancer cell growth.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12193537     DOI: 10.1210/en.2001-211408

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  56 in total

Review 1.  Investigational agents in development for the treatment of ovarian cancer.

Authors:  Shannon N Westin; Thomas J Herzog; Robert L Coleman
Journal:  Invest New Drugs       Date:  2012-06-04       Impact factor: 3.850

2.  Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.

Authors:  Danielle B Ulanet; Dale L Ludwig; C Ronald Kahn; Douglas Hanahan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-10       Impact factor: 11.205

Review 3.  The insulin-like growth factor system in cancer.

Authors:  S John Weroha; Paul Haluska
Journal:  Endocrinol Metab Clin North Am       Date:  2012-06       Impact factor: 4.741

Review 4.  Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer.

Authors:  Deepali Sachdev; Douglas Yee
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

5.  Differential expression of IGF components and insulin receptor isoforms in human seminoma versus normal testicular tissue.

Authors:  Tanja Pascale Neuvians; Isabella Gashaw; Andrea Hasenfus; Axel Hacherhäcker; Elke Winterhager; Rainer Grobholz
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

6.  Decorin differentially modulates the activity of insulin receptor isoform A ligands.

Authors:  Alaide Morcavallo; Simone Buraschi; Shi-Qiong Xu; Antonino Belfiore; Liliana Schaefer; Renato V Iozzo; Andrea Morrione
Journal:  Matrix Biol       Date:  2014-01-02       Impact factor: 11.583

7.  A role for candidate tumor-suppressor gene TCEAL7 in the regulation of c-Myc activity, cyclin D1 levels and cellular transformation.

Authors:  J Chien; K Narita; R Rattan; S Giri; R Shridhar; J Staub; D Beleford; J Lai; L R Roberts; J Molina; S H Kaufmann; G C Prendergast; V Shridhar
Journal:  Oncogene       Date:  2008-09-22       Impact factor: 9.867

8.  Insulin receptor isoform switching in intestinal stem cells, progenitors, differentiated lineages and tumors: evidence that IR-B limits proliferation.

Authors:  Sarah F Andres; James G Simmons; Amanda T Mah; M Agostina Santoro; Laurianne Van Landeghem; P Kay Lund
Journal:  J Cell Sci       Date:  2013-10-14       Impact factor: 5.285

9.  The role of dysregulated glucose metabolism in epithelial ovarian cancer.

Authors:  L D Kellenberger; J E Bruin; J Greenaway; N E Campbell; R A Moorehead; A C Holloway; J Petrik
Journal:  J Oncol       Date:  2010-02-17       Impact factor: 4.375

10.  New target genes for the peroxisome proliferator-activated receptor-γ (PPARγ) antitumour activity: Perspectives from the insulin receptor.

Authors:  Daniela P Foti; Francesco Paonessa; Eusebio Chiefari; Antonio Brunetti
Journal:  PPAR Res       Date:  2009-06-29       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.